177lu-psma-617
novartis
['pluvicto', 'refine ', ' vision', 'radio', 'prostate', 'novartis']
vision trial sub-studies refine pluvicto benefit as radiopharmaceutical access barriers persist. at asco, two sub-studies from the phase iii vision trial shed light on which prostate cancer patients are likely to benefit most from novartis' targeted... 